Neurocrine to Acquire Soleno, Gaining Drug for Prader-Willi Syndrome

Neurocrine Biosciences has announced its intention to acquire Soleno Therapeutics, a move that will secure a drug for Prader-Willi syndrome, a rare genetic disorder characterized by relentless hunger. The acquisition aims to expand Neurocrine's portfolio in rare diseases.